Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.
Lead Product(s): AS03,Recombinant protein-based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2020